Welcome to our dedicated page for BioNxt Solutions news (Ticker: BNXTF), a resource for investors and traders seeking the latest updates and insights on BioNxt Solutions stock.
BioNxt Solutions Inc. reports developments in bioscience and advanced drug delivery systems, with recurring updates on sublingual oral thin films, transdermal skin patches, oral enteric-coated tablets, diagnostic screening systems and active pharmaceutical ingredient development. Its lead program, BNT23001, is a proprietary sublingual cladribine oral thin film designed for relapsing forms of multiple sclerosis and other autoimmune neurodegenerative diseases.
Company news also covers patent protection for its oral thin-film technology, GMP manufacturing of clinical-grade cladribine film through a European CDMO, semaglutide as an initial GLP-1 oral thin-film application, commercialization planning, and capital-structure actions such as shares issued to settle debt.
BioNxt (OTCQB:BNXTF) closed a non-brokered LIFE private placement of 6,060,606 units at $0.33 each, for gross proceeds of $1,999,999.98. Each unit includes one share and one warrant exercisable at $0.50 for 24 months.
BioNxt paid $120,000 in cash finder’s fees and issued 363,636 finder’s warrants at $0.50 for 24 months. Proceeds are earmarked for European R&D, operations, working capital and general corporate purposes. An extension of unsecured convertible debentures is expected to close around July 10, 2026, pending approvals.
BioNxt Solutions (OTCQB:BNXTF) engaged a Business Development & Licensing advisor to support commercialization of BNT23001, its patented sublingual Cladribine orally dissolvable film for multiple sclerosis.
The advisor will refine commercial positioning and partnering strategy as BioNxt prepares a planned human bioavailability study comparing BNT23001 10 mg with Mavenclad® 10 mg tablets.
BioNxt Solutions (OTC:BNXTF) announced a non-brokered private placement of up to 6,060,606 Units at $0.33 per Unit for maximum gross proceeds of about $2,000,000 under the LIFE exemption.
Each Unit includes one share and a two-year warrant at $0.50. Proceeds will fund European R&D, operations, and general working capital.
BioNxt Solutions (OTCQB:BNXTF) amended terms of several unsecured convertible debentures with principal amounts ranging from $285,000 to $1,600,000, all bearing 8% interest. Maturities are extended by one year to dates between November 12, 2027 and March 14, 2028.
As consideration, BioNxt will issue 16,900,000 common share purchase warrants, each exercisable at $0.50 per share for 12 months. Warrants, related shares, and conversion shares carry a four‑month‑plus‑one‑day hold and require regulatory and corporate approvals, including from the Canadian Securities Exchange.
BioNxt (OTCQB:BNXTF) advanced its Semaglutide oral dissolvable film (ODF) program into active pharmaceutical development with partner Gen-Plus in Germany. The first phase, expected to last 6–9 months, covers formulation, analytical method development, compatibility testing, and proof-of-concept work once Semaglutide API is received.
The sublingual thin film targets the expanding GLP-1 market for obesity, metabolic disorders, and type 2 diabetes. BioNxt plans to leverage experience and preclinical results from its Cladribine ODF program to support future optimization, scale-up, and potential IP for Semaglutide and other candidates.
BioNxt (OTCQB:BNXTF) completed GMP manufacturing of a clinical-grade sublingual Cladribine oral thin film (BNT23001) at a Munich CDMO on April 14, 2026.
The GMP batch will serve as Investigational Medicinal Product supply for the planned CBN26001 human bioavailability study versus Mavenclad, and stability studies have been initiated to support Qualified Person release.
BioNxt (OTCQB:BNXTF) secured unitary effect for European Patent No. 4539857 covering its sublingual cladribine oral thin film (ODF) platform, registered March 31, 2026 with effect from March 11, 2026.
The unitary patent provides centralized protection across 18 European countries, strengthens IP for lead candidate BNT23001, and supports regional licensing, co-development and commercialization efforts. The patent claims a cladribine-cyclodextrin complex in a hydrophilic polymer ODF for transmucosal delivery; preclinical data show comparable systemic exposure to Mavenclad and a human bioavailability study is underway.
BioNxt (OTCQB:BNXTF) announced that semaglutide is its lead candidate to validate a sublingual oral thin-film (ODF) GLP-1 delivery platform. The program is in early-stage formulation and proof-of-concept work while the company targets broader peptide applications and intellectual property around carrier systems and films.
The release cites a large GLP-1 market (USD 62.83B in 2025, projected to USD 254.19B by 2034) and positions the platform for licensing and lifecycle management opportunities.
BioNxt Solutions (OTCQB:BNXTF) is shifting into commercialization after expanding global patent protection for its sublingual thin-film drug delivery platform and pursuing an accelerated U.S. Track One patent review.
Key items: European patent granted March 11, 2026; Eurasian patent granted Nov 14, 2025; U.S. Track One filing with ~9–12 month expected review; national phase filings in Canada, Japan, Australia, New Zealand. The lead product BNT23001 targets multiple sclerosis and myasthenia gravis.
BioNxt (OTCQB:BNXTF) signed a non-binding LOI on March 17, 2026, to negotiate exclusive commercialization terms for its sublingual cladribine oral thin film (ODF) across one or more EAPO member states, with a 60-day exclusive negotiation period.
BioNxt has EAPO Patent No. 051510 (issued Nov 14, 2025) covering eight Eurasian states and European Patent No. 4539857 (published Mar 11, 2026); both patents are stated as valid through at least June 14, 2043. The LOI contemplates upfronts, royalties, and revenue sharing, and BioNxt is preparing a human bioequivalence study.